Loges Team’s Post

Fred Howard, MD, Alexander Pearson, MD, PhD and colleagues published a great study in Journal of Clinical Oncology Clinical Cancer Informatics during American Society of Clinical Oncology (ASCO) annual meeting reporting increased use of #ChatGPT in scientific writing, warning authors to be responsible for accurate representation of content. #ASCO24 #AIToolsInScienceWriting The University of Chicago Section of Hematology/Oncology University of Chicago Medicine Comprehensive Cancer Center https://ow.ly/hUTB50Sim17

Join us at #ESMO2024 in Barcelona for an exciting overview of the initial results of the TRIDENT study! 📅 September 14th at 12h CEST Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center Save the date and meet us to discover how SOPHiA GENETICS and AstraZeneca are applying multimodal approaches in cancer drug development. See you there! ESMO - European Society for Medical Oncology #ESMO #PrecisionOncology #PrecisionMedicine #AIforHealthcare #DeepLearning #Multimodal #DataAnalytics #DataDrivenMedicine #Oncology

I am thrilled to share our recent publication entitled "Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay" in Medical Oncology Journal, Q2 Thanks for the whole team https://lnkd.in/dYRBB_zF

Taste the Future: #AI, Precision Oncology, & Clinical Trials with Massive Bio at #ASCO24 – Innovation in Every Bite! We got over 25,000 pieces of them. Visit the Massive Bio booth #29137 for exclusive demos. When you savor or share one of these M&Ms, remember our mission to make cancer #ClinicalTrials trials accessible to every patient worldwide. Join us in transforming oncology research! #CancerResearch Selin Kurnaz, PhD | Çağatay M. Çulcuoğlu

Just published in CA: A Cancer Journal for Clinicians in time for #ASCO24 📕 🎯 The evolving landscape of tissue-agnostic therapies in precision oncology: https://lnkd.in/gBGsMEni Tumor-agnostic therapies represent a paradigm shift in oncology. This review by Vivek Subbiah, MD, Mohamed A. Gouda MD, Bettina Ryll MD, PhD, Skip Burris MD, and Razelle Kurzrock MD delves into the expansive landscape of tissue-agnostic targets and drugs. #PrecisionMedicine

Fusobacterium—a genus of anaerobic, rod-shaped bacteria commonly found in the human oral cavity—plays a surprising dual role in cancer. Recent studies reveal its involvement in both tumor progression and the potential induction of apoptosis in cancer cells. Could this common microbe be a game-changer in cancer therapy? Learn more about this intriguing possibility in my latest article. #Microbiome #CancerResearch #Oncology #Fusobacterium #HealthcareInnovation #MedicalWriting"

📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC - Elisa Agostinetto JAMA Oncology OncoAlert #BreastCancer #Research #Cancer #HER2E #JAMAOncology #OncoDaily #Oncology #PCR #TumorSubtypes

I'm happy to share that our paper, "Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis," has garnered significant attention and is among the most viewed papers at the International Journal of Molecular Sciences MDPI. It's gratifying to see the interest in our work, and I'm proud of the contribution our research is making to the field of oncology. Link: https://lnkd.in/eAskpqKQ #CancerResearch #LiquidBiopsy #LungCancer

✍ Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland 👇 ✅ This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates. ✅ Results showing the clinical utility of the test have been published in Lancet Oncology and the Journal of National Cancer Institute. ✅ The MAF Test® is now available to oncologists and pathologists in United Kingdom and Ireland and will benefit an estimated 56,000 new patients each year. ✅ This agreement follows Inbiomotion’s recent distribution partnerships for Spain and Portugal with Palex Medical and The Scientific Group for Sub-Saharan Africa. Read more here 🔗 shorturl.at/cLMR3 #BeastCancer #CancerResearch #innovation #IRBInnovation #metastasis #MetastasisResearch